PMID- 32462110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230425
IS  - 2475-5303 (Print)
IS  - 2475-5311 (Electronic)
IS  - 2475-5303 (Linking)
VI  - 5
IP  - 2
DP  - 2020 Apr
TI  - Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis.
PG  - 61-67
LID - 10.1177/2475530320910814 [doi]
AB  - BACKGROUND: Diagnosis of psoriatic arthritis (PsA) can be challenging, resulting 
      in delays that contribute to irreversible joint damage, reduced quality of life, 
      and increased mortality. OBJECTIVE: Use genetic markers to develop and evaluate a 
      PsA genetic risk score (GRS) for its ability to discriminate between psoriasis 
      (PsO) only and PsO with PsA among a psoriatic cohort with full genome-wide 
      genotype data. METHODS: Genome-wide single-nucleotide polymorphism genotyping was 
      performed on 724 psoriatic patients. A set of 11 candidate risk genes previously 
      shown to be preferentially associated with PsO or PsA were selected. To evaluate 
      the cumulative effects of these risk loci, a PsA GRS was developed using an 
      unweighted risk allele count (cGRS) and a weighted (wGRS) approach. Additional 
      analyses included only human leukocyte antigen (HLA) risk alleles. RESULTS: The 
      discriminative power attributable to each GRS was evaluated by calculating the 
      areas under the receiver operator characteristic curve (AUROC). The AUROC for the 
      wGRS is 56.2% versus 54.1% for the cGRS, and the AUROC for the HLA-only wGRS 
      model was 56.9% versus 55.7% for the HLA-only cGRS. CONCLUSION: The AUROC of 
      56.9% for HLA-only wGRS indicates that this approach has the greatest power in 
      discriminating PsA from PsO among these models. Given that an AUROC of 56.9% is 
      quite modest, this study suggests that using a small number of well-validated 
      genetic loci provides limited predictive power for PsA, and that future 
      approaches may benefit from using a larger number of genetic loci.
FAU - Smith, Mary Patricia
AU  - Smith MP
AUID- ORCID: 0000-0002-1225-8944
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Ly, Karen
AU  - Ly K
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Thibodeaux, Quinn
AU  - Thibodeaux Q
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Beck, Kristen
AU  - Beck K
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Yang, Eric
AU  - Yang E
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
AD  - Chicago Medical School, Rosalind Franklin University of Medicine and Science, 
      North Chicago, IL, USA.
FAU - Sanchez, Isabelle
AU  - Sanchez I
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
AD  - Department of Dermatology, University of Illinois at Chicago, IL, USA.
FAU - Nititham, Joanne
AU  - Nititham J
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Bhutani, Tina
AU  - Bhutani T
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
FAU - Liao, Wilson
AU  - Liao W
AUID- ORCID: 0000-0001-7883-6439
AD  - Department of Dermatology, University of California, San Francisco, CA, USA.
LA  - eng
GR  - NPF2018SSRG11/NPF_/National Psoriasis Foundation/United States
GR  - R01 AR065174/AR/NIAMS NIH HHS/United States
GR  - U01 AI119125/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20200304
PL  - United States
TA  - J Psoriasis Psoriatic Arthritis
JT  - Journal of psoriasis and psoriatic arthritis
JID - 101695066
PMC - PMC7252226
MID - NIHMS1590289
OTO - NOTNLM
OT  - blood tests
OT  - diagnosis
OT  - psoriasis
OT  - psoriatic arthritis
OT  - symptoms
COIS- Declaration of Conflicting Interests The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article. Tina Bhutani has served as a research investigator 
      and/or consultant for Eli Lilly, Janssen, Merck, Celgene, and Regeneron. Wilson 
      Liao has served as a research investigator for Abbvie, Amgen, Janssen, Novartis, 
      Pfizer, and Regeneron.
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:01
PMCR- 2020/05/27
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:01 [medline]
PHST- 2020/05/27 00:00 [pmc-release]
AID - 10.1177/2475530320910814 [doi]
PST - ppublish
SO  - J Psoriasis Psoriatic Arthritis. 2020 Apr;5(2):61-67. doi: 
      10.1177/2475530320910814. Epub 2020 Mar 4.